In Business 32 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 32 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[Immunomycin] [FK-520] [FR 900520] [L 683590]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
5 mg |
43 |
33 |
27 |
3300 |
| ||
|
25 mg |
115 |
87 |
73 |
8800 |
| ||
|
100 mg |
375 |
285 |
237 |
28700 |
| ||
|
300 mg |
890 |
676 |
563 |
68200 |
| ||
|
1 g |
1975 |
1500 |
1248 |
151400 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Prices and Purity — LC Labs vs. Other Suppliers |
|---|
M.W. 792.01
C43H69NO12
[104987-12-4]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 65 mg/mL; soluble in ethanol at 50 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Ascomycin (also known as Immunomycin, FR 900520, and FK-520) is an analog of tacrolimus (FK-506) with immunosuppressive, neurotrophic and antifungal activities. Ascomycin can be used to prevent rejection after an organ transplant, and to treat autoimmune diseases and skin diseases.
Ascomycin inhibits the production of T helper type 1 (Th1) (interferon and IL-2) and Th2 (IL-4 and IL-10) cytokines in target cells. Paul, C., et al. "Ascomycins: promising agents for the treatment of inflammatory skin diseases." Expert Opin. Investig. Drugs. 9: 69-77 (2000). Mollison, K.W., et al. "A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases." J. Invest. Dermatol. 112: 729-738 (1999).
Antimalarial effects of ascomycin appear to be independent of its immunosuppressive properties. Monaghan, P., et al. "Antimalarial effects of macrolactones related to FK520 (ascomycin) are independent of the immunosuppressive properties of the compounds." J. Infect. Dis. 191: 1342-1349 (2005).
FK-520 might be a substrate for P-glycoprotein; expression of P-glycoprotein in yeast cells resulted in resistance to growth inhibition by FK-520. Raymond, M., et al. "Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520." Mol. Cell Biol. 14: 277-286 (1994).
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
Please see also our other standard immunosuppressant products:
Our products are for laboratory research only and are sold only to qualified research institutions, not to individuals or patients nor for veterinary use.
